Fulcrum Asset Management’s Harmony Biosciences HRMY Stock Holding History

Fulcrum Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97.6K	Buy	+2,762	New	+$87.1K	0.01%	497

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fulcrum Asset Management's HRMY Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in Harmony Biosciences (HRMY) in Q2 2026: 2,762 shares worth $97.6K. The stake represents 0.01% of the portfolio and ranks #497 among its holdings.

326 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Fulcrum Asset Management held 2,762 shares of Harmony Biosciences worth $97.6K as of Q2 2026.
Harmony Biosciences was a new Fulcrum Asset Management position in Q2 2026.
Harmony Biosciences made up 0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #497 holding.
326 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.